Marksans Pharma Limited (NSE: MARKSANS, BSE: 524404) announced that its wholly owned UK-based subsidiary, Relonchem Limited, has received Marketing Authorization from the UK Medicines and Healthcare products Regulatory Agency (MHRA) for three key anti-diabetic products.
The approvals cover:
-
Metformin Hydrochloride Relonchem 500 mg Prolonged Release Tablets
-
Metformin Hydrochloride Relonchem 750 mg Prolonged Release Tablets
-
Metformin Hydrochloride Relonchem 1000 mg Prolonged Release Tablets
Metformin is among the most widely prescribed medications for the treatment of type 2 diabetes, playing a crucial role in blood sugar management. With this authorization, Relonchem will be able to expand its presence in the UK market and further strengthen Marksans Pharma’s position in the global anti-diabetic segment.
Headquartered in Mumbai, Marksans Pharma operates manufacturing facilities in India, the USA, and the UK, all of which are approved by global regulators including USFDA, UKMHRA, and TGA. The company has a diversified product portfolio spanning cardiovascular, central nervous system, anti-diabetic, pain management, gastroenterology, and anti-allergy therapies.